Medical/Pharmaceuticals

IND Approved for Pivotal Clinical Study of HER2 Bispecific Antibody KN026 Combined with Chemotherapy in Gastric Cancer

SUZHOU, China, Jan. 5, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced that the IND application for the pivotal clinical trial (KN026-CSP-001) of the anti-HER2 bispecific antibody KN026 combined with che...

2022-01-05 11:49 5337

COVID-19 Oral Vaccine and Antibody Booster: B. subtilis Spores, Biotechnology Breakthrough by DreamTec

HONG KONG, Jan. 5, 2022 /PRNewswire/ -- Vaccines have been a trending topic ever since the coronavirus outbreak two years ago. DreamTec Research Limited (DreamTec,http://www.dreamtec.hk ) has its major breakthrough in developing a COVID-19 oral vaccine. In its recently pu...

2022-01-05 10:00 5732

PRISM BioLab, enters multi-project drug discovery collaboration with Roche and Genentech

TOKYO, Jan. 4, 2022 /PRNewswire/ -- PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, today announced it has entered into a multi-target research collaboration and licensing agreement with Roche and Genentech, a member of ...

2022-01-05 09:00 2881

BIORCHESTRA, SK Biopharmaceuticals collaborate to develop miRNA-targeted therapeutics

SEOUL, South Korea, Jan. 4, 2022 /PRNewswire/ -- BIORCHESTRA and SK Biopharmaceuticals announcedtoday that they have forged a partnership to research and develop new therapeutic compounds targeting microRNAs [1] (miRNA) for a potential treatment of epilepsy.

2022-01-05 08:07 2782

SI GROUP APPOINTS RUSTOM JILLA AS NEW CHIEF FINANCIAL OFFICER

Jilla brings nearly 20 years of international CFO experience including transformational change SCHENECTADY, N.Y., Jan. 5, 2022 /PRNewswire/ -- SI Group, a leading performance additives company, announced today the appointment ofRustom Jilla as its Senior Vice President and Chief Financial Office...

2022-01-05 02:00 4259

CAI Announces CEO Succession

INDIANAPOLIS, Jan. 4, 2022 /PRNewswire/ -- CAI, a global consulting company that provides technical, operational consulting, and project management services to life sciences, data centers, and industrial process manufacturing industries, today announcedMichael Martin, CAI President, will succeed ...

2022-01-04 22:33 6103

Molecular Stethoscope, Inc. establishes new Corporate Headquarters and Research & Development Laboratories in South San Francisco and appoints Gajus Worthington to its Board of Directors

SOUTH SAN FRANCISCO, Calif., Jan. 4, 2022 /PRNewswire/ -- Molecular Stethoscope, a leading Precision Medicine biotechnology company pioneering the next-generation cf-mRNA Liquid Biopsy, announced today that it has joined Verily Life Sciences ("Verily") partnered laboratory ecosystem inSouth San ...

2022-01-04 19:00 1998

Harbour BioMed Announces Dosing of First Patient of Two Phase I Trials for Next-Generation Anti-CTLA-4 Antibody HBM4003

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Jan. 4, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that, its next generation anti-CTLA-4 fully human heavy-chain only antibody (HCAb), HBM4003, has completed the first dosing of first patient in two phase I tri...

2022-01-04 17:28 2729

Alamar Biosciences partners with Abcam to drive understanding of the human proteome

FREMONT, Calif. and CAMBRIDGE, England, Jan. 4, 2022 /PRNewswire/ -- Alamar Biosciences  (Alamar), a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases, and Abcam (AIM: ABC...

2022-01-04 17:00 3098

AKESO'S CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) COMBINED WITH CONCURRENT CHEMORADIOTHERAPY OBTAINED APPROVAL TO INITIATE A PHASE III CLINICAL TRIAL FOR THE TREATMENT OF LOCALLY ADVANCED CERVICAL CANCER

HONG KONG, Jan. 3, 2022 /PRNewswire/ -- Today, Akeso (09926.HK) announces that Cadonilimab (PD-1/ CTLA-4 bi-specific antibody), the first-inclass novel immuno-oncology drug independently developed by the Company, combined with concurrent chemoradiotherapy obtained approval from the Center for Dru...

2022-01-04 10:00 3175

Breakthrough Discoveries on Novel Features of Omicron Variant and An Anti-Omicron Antibody JMB2002

SHANGHAI, Jan. 4, 2022 /PRNewswire/ -- Joint research results from Biologics of Jemincare and Shanghai Institute ofMateria Medica (SIMM) of Chinese Academy of Sciences (CAS) confirmed that JMB2002, an anti-SARS-CoV-2 neutralizing antibody (NAb) discovered by Biologics of Jemincare is still effect...

2022-01-04 10:00 5523

Gannex Announces Completion of the U.S. Phase I Trial of ASC43F, an In-House Developed First-in-Class Dual Targeting Fixed-dose Combination Tablet for NASH

* ASC43F was safe and well tolerated in healthy subjects with no clinically significant study drug related adverse events * Pharmacokinetic parameters of ASC41 and ASC42 from ASC43F are similar to those of ASC41 and ASC42 monotherapy * Phase I trial completed two months after the U.S. IND ap...

2022-01-04 08:30 4611

Asieris Announces the World's First Patient Dose Administered in Combination of Asieris'APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients

SHANGHAI, Jan. 3, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris), a global innovative pharma company specializing in new drugs for the treatment of genitourinary tumors, today announced that the world's first patient dose has been administered in U.S. for its oral APL-1202 in combination ...

2022-01-04 08:06 2172

Everest Medicines Announces Taiwan FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer

SHANGHAI, Jan. 4, 2022 /PRNewswire/ -- Everest Medicines Limited (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products inAsia, announced today that T...

2022-01-04 08:00 5301

Biosion, Inc. Appoints Anthony Yeh, Ph.D., as Chief Strategy Officer and Head of China BD

NEWARK, Del. and NANJING, China, Jan. 3, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical stage biotechnology company, today announced the appointment of Dr.Anthony Yeh to the position of Chief Strategy Officer and Head ofChina business development (BD), where he will lead corpor...

2022-01-03 18:00 2639

Sihuan Pharmaceutical (0460.HK): Sunshine Life Insurance Leads Investment in Xuanzhu Biopharm

HONG KONG, Jan. 3, 2022 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; Hong Kong Stock Exchange stock code: 0460) is pleased to announce that, its subsidiary Xuanzhu...

2022-01-03 14:24 8043

Ascletis Expands Ritonavir Oral Tablet Production and Announces Oral Direct-Acting Antiviral Pipeline Against SARS-CoV-2 Virus

- Ritonavir oral tablet annual production capacity has been expanded to 100 million tablets and can be further rapidly expanded based on market demand - ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection - ASC11 is ...

2022-01-03 08:30 4886

CStone Pharmaceuticals announced the IND approval of CS5001, a potential global best-in-class ROR1-targeting ADC by the U.S. Food and Drug Administration

SUZHOU, China, Jan. 3, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the investigational new ...

2022-01-03 08:00 5205

Pulnovo Medical Announced Results From PADN-CFDA Pivotal Trial For The Treatment Of Pulmonary Arterial Hypertension (PAH) Meet The Efficacy Primary Endpoint

SHANGHAI, Jan. 1, 2022 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized device pioneer in treatment for cardiopulmonary disease, today announced the positive results from the Pulmonary Artery Denervation (PADN)-CFDA pivotal study, being the first global completed pulmonary hyperten...

2022-01-01 20:30 3460

I-Mab Announces Upcoming Participation at January Conferences

SHANGHAI and GAITHERSBURG, MD., Dec. 31, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced its participation in the following conferences inJanuar...

2021-12-31 21:00 3598
1 ... 613614615616617618619 ... 644